Skip to main content
735 search results for:

GIP-GLP-1 Agonists 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 01-12-2023 | Insulins | ReviewPaper

    Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

    Type 2 diabetes (T2D) is a chronic metabolic condition marked by hyperglycaemia that requires stepwise addition of multiple glucose-lowering medications as the disease progression [ 1 , 2 ]. The net result is a viscous cycle of hyperglycaemia …

  2. Open Access 12-03-2024 | Diabetic Nephropathy | Review

    Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future

    Cardiovascular outcome trials indicate that incretin-based therapies have renal benefits beyond their glucose-lowering efficacy. But what is the evidence regarding the nephroprotective effects of these anti-diabetes compounds?

  3. 12-02-2024 | Diabetes Therapy | News | Article

    Pros and cons of GLP-1 receptor agonists for type 2 diabetes

    A comprehensive network meta-analysis has validated the efficacy of 15 GLP-1 receptor agonists for the treatment of type 2 diabetes, but also highlighted the risk for gastrointestinal adverse events.

  4. Open Access 25-07-2023 | Prediabetes | BriefCommunication

    Should Prediabetes be Treated Pharmacologically?

  5. Open Access 28-06-2023 | Obesity | ReviewPaper

    Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?

    Obesity is characterized by a disproportion between caloric intake and energy expenditure (EE) and is frequently associated with high glucose and lipid serum levels [ 1 ], as well as by several comorbidities, such as cardiovascular, metabolic …

  6. Open Access 04-04-2024 | Obesity | ReviewPaper

    Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes

    The discovery of long-acting incretin receptor agonists represents a major stride forward in tackling the dual epidemic of obesity and diabetes. Here we outline the evolution of incretin-based pharmacotherapy, from exendin-4 to the discovery of …

  7. Open Access 20-05-2023 | Obesity | ReviewPaper

    Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy

    Glucagon-like peptide-1 (GLP-1) receptor agonists are established pharmaceutical therapies for the treatment of type 2 diabetes and obesity. They mimic the action of GLP-1 to reduce glucose levels through stimulation of insulin secretion and …

  8. 30-04-2024 | Obesity | Online First

    Update on Pediatric Anti-obesity Medications—Current Landscape and Approach to Prescribing

    Obesity is a chronic disease with related comorbidities including hypertension, dyslipidemia, type 2 diabetes, nonalcoholic fatty liver disease, obstructive sleep apnea, musculoskeletal problems, and psychosocial issues. Patients benefit most from …

  9. 08-02-2023 | Obesity | ReviewPaper

    Obesity Pharmacotherapy: a Review of Current Practices and Future Directions

    Obesity is a chronic disease that increases the risk of morbidity from type 2 diabetes, hyperlipidemia, hypertension, stroke, and some cancers. Obesity is associated with increased risk of cardiovascular and all-cause mortality [ 1 ]. The World …

  10. 05-05-2024 | Acute Pancreatitis | Online First

    The effect of incretin-based drugs on the riks of acute pancreatitis: a review

    In recent years, new hypoglycaemic drugs which affect the incretin system have gained increasing popularity in the treatment of type 2 diabetes mellitus (T2DM). Currently, two groups of incretin-based agents are available: glucagon-like peptide 1

  11. Open Access 01-12-2022 | Insulins | ReviewPaper

    Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

    Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an acylated peptide engineered to activate the GIP and GLP-1 receptors, key mediators of …

  12. 01-06-2024 | Breast Cancer | OriginalPaper

    Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells

    Breast cancer (BC) is associated with type 2 diabetes mellitus (T2DM) and obesity. Glucagon-like peptide (GLP)-1 regulates post-prandial insulin secretion, satiety, and gastric emptying. Several GLP-1 analogs have been FDA-approved for the …

  13. Open Access 01-12-2024 | Tirzepatide | OriginalPaper

    Evidence that tirzepatide protects against diabetes-related cardiac damages

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used antidiabetic drugs, are approved and recommended in several treatment guidelines for reducing the risk of major adverse cardiovascular events (MACE), such as cardiovascular death …

  14. 21-12-2023 | Semaglutide | ReviewPaper

    Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges

    The use of glucagon-like peptide-1 (GLP-1) receptor-based multi-agonists in the treatment of type 2 diabetes and obesity holds great promise for improving glycaemic control and weight management. Unimolecular dual and triple agonists targeting …

  15. Open Access 01-12-2024 | Semaglutide | Letter

    CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes

    The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange …

  16. 27-03-2024 | Pancreatectomy | Online First

    Advances in the clinical measurement of glucagon: from diagnosis to therapy

    Glucagon has many functions: it promotes glucose production, fatty acid oxidation, thermogenesis, energy consumption, lipolysis, and myocardial contraction, and suppresses lipogenesis, appetite, and gastrointestinal motility. Which of these …

  17. 23-02-2024 | Tirzepatide | ReviewPaper

    Tirzepatide: A Review in Type 2 Diabetes

    Tirzepatide (Mounjaro®), a first-in-class dual incretin agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, is approved for use as an adjunct to diet and exercise to improve glycaemic …

  18. Open Access 01-12-2024 | OriginalPaper

    Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males

    Glucagon is secreted from pancreatic alpha cells and increases blood glucose but also influences hepatic protein and lipid metabolism during mixed meals [ 1 ]. Especially amino acids stimulate the secretion of glucagon from the alpha cell [ 2 ].

  19. Open Access 12-03-2024 | Liraglutide | Online First

    Animal studies on glucagon-like peptide-1 receptor agonists and related polyagonists in nonalcoholic fatty liver disease

    Nonalcoholic fatty liver disease (NAFLD) is a prevalent metabolic liver disease closely associated with the epidemics of obesity and type 2 diabetes mellitus (T2DM), but without licensed pharmacological treatment to date. As glucagon-like …

  20. Free for a limited time 15-04-2024 | Endocrinology | Review

    Highlights from EndoBridge 2023

    Everything you need to know from EndoBridge 2023. Find out the latest developments across all aspects of endocrinology and metabolism, and learn about the clinical approaches to common endocrine issues.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.